Al[¹⁸F]F-NOTA-Octreotide Is Comparable to [⁶⁸Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population.

ABSTRACT: PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [⁶⁸Ga]Ga-DOTA-TATE. Al[¹⁸F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [⁶⁸Ga]Ga-DOTA-TATE and Al[¹⁸F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [⁶⁸Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[¹⁸F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adr

SUBMITTER: Haeger A 

PROVIDER: S-EPMC9856643 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature